ProfileGDS5678 / 1445260_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 85% 83% 84% 82% 83% 87% 86% 85% 84% 83% 84% 87% 85% 85% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.3136685
GSM967853U87-EV human glioblastoma xenograft - Control 26.1482383
GSM967854U87-EV human glioblastoma xenograft - Control 36.1698384
GSM967855U87-EV human glioblastoma xenograft - Control 46.1407982
GSM967856U87-EV human glioblastoma xenograft - Control 56.1459283
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.4395887
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.4061386
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.2734285
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.180784
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.1879983
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.2450684
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.7237387
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.2914585
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.2991685